These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Villa C; Vasiljevic A; Jaffrain-Rea ML; Ansorge O; Asioli S; Barresi V; Chinezu L; Gardiman MP; Lania A; Lapshina AM; Poliani L; Reiniger L; Righi A; Saeger W; Soukup J; Theodoropoulou M; Uccella S; Trouillas J; Roncaroli F Virchows Arch; 2019 Dec; 475(6):687-692. PubMed ID: 31578606 [TBL] [Abstract][Full Text] [Related]
3. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors. Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163 [TBL] [Abstract][Full Text] [Related]
4. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1. Asa SL; Mete O; Riddle ND; Perry A Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858 [TBL] [Abstract][Full Text] [Related]
6. Overview of the 2022 WHO Classification of Pituitary Tumors. Asa SL; Mete O; Perry A; Osamura RY Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028 [TBL] [Abstract][Full Text] [Related]
7. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Mete O; Asa SL Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs. Inoshita N; Yoshimoto T; Takazawa Y; Fukuhara N; Okada M; Nishioka H; Yamada S Brain Tumor Pathol; 2023 Jul; 40(3):158-162. PubMed ID: 37072666 [TBL] [Abstract][Full Text] [Related]
9. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience. Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981 [No Abstract] [Full Text] [Related]
10. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version]. Xie J; Wu ZB Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420 [TBL] [Abstract][Full Text] [Related]
11. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967 [TBL] [Abstract][Full Text] [Related]
12. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features. Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887 [TBL] [Abstract][Full Text] [Related]
13. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset. Luo M; Tang R; Wang H J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology. Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B Arch Pathol Lab Med; 2025 Jan; 149(1):83-89. PubMed ID: 38649148 [TBL] [Abstract][Full Text] [Related]